Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT04655976 · ClinicalTrials.gov registry record · Phase 3

Efficacy Comparison of Cobolimab + Dostarlimab + Docetaxel to Dostarlimab + Docetaxel to Docetaxel Alone in Participants With Advanced Non-small Cell Lung Cancer Who Have Progressed on Prior Anti-PD-(L)1 Therapy and Chemotherapy

A Phase 3 study of Lung Cancer, Non-Small Cell, sponsored by GlaxoSmithKline.

Active
Registry status
Phase 3
Development phase
758
Enrollment target
20
Study locations

NCT04655976 is a Phase 3 study of Lung Cancer, Non-Small Cell that is active but no longer recruiting, run by GlaxoSmithKline. The registered enrollment target is 758 participants, above the 255-participant average among 10 other Lung Cancer, Non-Small Cell trials with a reported enrollment target (197% higher). The trial reports 20 study locations across 14 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT04655976, a Phase 3 study of Lung Cancer, Non-Small Cell, is active but no longer recruiting, sponsored by GlaxoSmithKline.

ACTIVE NOT RECRUITING
Registry status
Phase 3
Development phase
758 participants
Enrollment target
20
Study locations

Study Summary

This is a multi-center, parallel group treatment, Phase 2/3 open label study evaluating cobolimab in combination with dostarlimab and docetaxel in participants with advanced non-small cell Lung Cancer (NSCLC) who have progressed on prior anti-PD-(L)1 therapy and chemotherapy.

Conditions Studied

Lung Cancer, Non-Small Cell

Interventions

  • DRUG Docetaxel
  • BIOLOGICAL Dostarlimab
  • BIOLOGICAL Cobolimab

Study Locations (20)

New York

  • GSK Investigational Site - Mineola
  • GSK Investigational Site - New York
  • GSK Investigational Site - White Plains

Other

  • GSK Investigational Site - Buenos Aires
  • GSK Investigational Site - Cipoletti Rio Negro
  • GSK Investigational Site - Ciudad Autonoma de Buenos Aire

California

  • GSK Investigational Site - Fountain Valley
  • GSK Investigational Site - Walnut Creek

Pennsylvania

  • GSK Investigational Site - Pittsburgh
  • GSK Investigational Site - Pittsburgh

Connecticut

  • GSK Investigational Site - Norwich

District of Columbia

  • GSK Investigational Site - Washington D.C.

Hawaii

  • GSK Investigational Site - Honolulu

Iowa

  • GSK Investigational Site - Iowa City

Trial Details

FieldValue
Enrollment Target 758 participants
Start Date 2020-12-08
Est. Completion 2027-03-30
Phase Phase 3

Sponsor

GlaxoSmithKline

1,345 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT04655976

The ClinicalTrials.gov registry entry for NCT04655976 describes a study currently listed as active not recruiting, categorized as Phase 3. The registered enrollment target is 758 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 255-participant average among 10 other Lung Cancer, Non-Small Cell trials with a reported enrollment target (197% higher). The listed sponsor is GlaxoSmithKline, which has 1,345 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Lung Cancer, Non-Small Cell appearing as the primary indexed condition, and to 3 interventions - of which Docetaxel is the first listed.

NCT04655976 reports 20 study locations spanning 14 distinct geographic areas - top geographies include New York, Other, California.

Frequently Asked Questions

What is clinical trial NCT04655976 about?

NCT04655976 is a clinical study titled "Efficacy Comparison of Cobolimab + Dostarlimab + Docetaxel to Dostarlimab + Docetaxel to Docetaxel Alone in Participants With Advanced Non-small Cell Lung Cancer Who Have Progressed on Prior Anti-PD-(L)1 Therapy and Chemotherapy". This is a multi-center, parallel group treatment, Phase 2/3 open label study evaluating cobolimab in combination with dostarlimab and docetaxel in participants with advanced non-small cell Lung Cancer (NSCLC) who have progressed on prior anti-PD-(L)1 therapy and chemotherapy.

What is the current status of trial NCT04655976?

This trial is currently active not recruiting. It is a Phase 3 study. The enrollment target is 758 participants. The study started on 2020-12-08. Estimated completion is 2027-03-30.

What conditions does trial NCT04655976 study?

This clinical trial studies the following conditions: Lung Cancer, Non-Small Cell.

What interventions are being tested in trial NCT04655976?

The interventions under investigation include: Docetaxel (DRUG), Dostarlimab (BIOLOGICAL), Cobolimab (BIOLOGICAL).

Who is sponsoring clinical trial NCT04655976?

This trial is sponsored by GlaxoSmithKline, which has 1,345 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT04655976 being conducted?

This trial has 20 study locations across California, Connecticut, District of Columbia, Hawaii, Iowa. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Lung Cancer, Non-Small Cell

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Lung Cancer, Non-Small Cell

All registered trials for this condition

California

All trials with a study site in California

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.